ES2535961T3 - Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia - Google Patents

Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia Download PDF

Info

Publication number
ES2535961T3
ES2535961T3 ES10181686.6T ES10181686T ES2535961T3 ES 2535961 T3 ES2535961 T3 ES 2535961T3 ES 10181686 T ES10181686 T ES 10181686T ES 2535961 T3 ES2535961 T3 ES 2535961T3
Authority
ES
Spain
Prior art keywords
mutation
virulence gene
attenuated
seq
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10181686.6T
Other languages
English (en)
Inventor
David E. Lowery
Michael J. Kennedy
Troy E. Fuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis P&U LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis P&U LLC filed Critical Zoetis P&U LLC
Application granted granted Critical
Publication of ES2535961T3 publication Critical patent/ES2535961T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Una bacteria atenuada de Pasteurella multocida, que comprende una mutación en un gen representado por una secuencia polinucleotídica que codifica un polipéptido fhaC (i) en la que la secuencia polinucleotídica hibrida con el complemento de la SEC ID N.O: 19 en condiciones restrictivas, comprendiendo tales condiciones un lavado final en tampón que comprende SSC 2X/SDS al 0,1 %, a 35°C hasta 45°C, o (ii) en la que el polipéptido comprende una secuencia de aminoácidos al menos idéntica en un 80 % a la SEC ID NO: 20, en la que la atenuación de la bacteria está causada por dicha mutación.

Description

imagen1

Claims (1)

  1. imagen1
ES10181686.6T 1999-04-09 2000-04-06 Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia Expired - Lifetime ES2535961T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12868999P 1999-04-09 1999-04-09
US128689P 1999-04-09
US15345399P 1999-09-10 1999-09-10
US153453P 1999-09-10

Publications (1)

Publication Number Publication Date
ES2535961T3 true ES2535961T3 (es) 2015-05-19

Family

ID=26826843

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10181691.6T Expired - Lifetime ES2439645T3 (es) 1999-04-09 2000-04-06 Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
ES10181686.6T Expired - Lifetime ES2535961T3 (es) 1999-04-09 2000-04-06 Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES10181691.6T Expired - Lifetime ES2439645T3 (es) 1999-04-09 2000-04-06 Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia

Country Status (14)

Country Link
US (5) US20070237793A1 (es)
EP (5) EP2281835B1 (es)
JP (4) JP4892134B2 (es)
KR (4) KR20060116041A (es)
CN (1) CN1351653A (es)
AR (1) AR029622A1 (es)
AU (2) AU780887B2 (es)
BR (1) BR0009663A (es)
CA (1) CA2366520C (es)
ES (2) ES2439645T3 (es)
HK (1) HK1045856A1 (es)
MX (1) MXPA01010207A (es)
NZ (2) NZ530012A (es)
WO (1) WO2000061724A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045856A1 (zh) * 1999-04-09 2002-12-13 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4124732B2 (ja) 2001-09-26 2008-07-23 協和醗酵工業株式会社 α１，４−ガラクトース転移酵素およびガラクトース含有複合糖質の製造法
EP1350796B1 (en) * 2002-04-05 2009-01-07 Merial Attenuated gram negative bacteria
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
WO2004078965A1 (ja) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 大腸菌における異種蛋白質の製造方法
EP2073829B1 (en) * 2006-10-05 2012-06-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
WO2009137532A1 (en) 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
DE102011016772B8 (de) * 2011-04-12 2024-08-14 Mercedes-Benz Group AG Verfahren und Vorrichtung zur Überwachung zumindest eines Fahrzeuginsassen und Verfahren zum Betrieb zumindest einer Assistenzvorrichtung
EP3062816B1 (en) 2013-11-01 2020-08-05 Boehringer Ingelheim Animal Health USA Inc. Attenuated pasteurella multocida vaccines & methods of making & use thereof
ES2945137T3 (es) 2017-02-10 2023-06-28 Epitopix Llc Proteínas y composiciones inmunitarias que contienen proteínas de Pasteurella y métodos de uso
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
TW202219269A (zh) * 2020-09-30 2022-05-16 美國農業部 新型多殺性巴斯德氏菌株及具有ｈｙａＣ與ｎａｎＰ缺失之疫苗
CN113567415A (zh) * 2021-07-05 2021-10-29 广西大学 表面增强拉曼散射结合免疫层析技术检测布鲁氏杆菌方法
CN115925536B (zh) * 2022-08-01 2025-02-28 北京农学院 靶向抑制DksA的小分子抑制剂和应用
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL52815A (en) * 1977-08-24 1983-03-31 Israel State Fowl cholera vaccine and process for producing an attenuated non-virulent strain of pasteurella multocida
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3426532A1 (de) * 1984-07-18 1986-01-30 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verwendung einer dna-sequenz zur expression sowie dna-struktur und expressionsvektor mit der dna-sequenz
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
DK46693D0 (es) * 1993-04-23 1993-04-23 Novo Nordisk As
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
EP0668779A4 (en) * 1992-11-06 1996-08-21 Univ Minnesota Vaccine to protect against pasteurellosis - infection by P.multocida.
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
DE19502584C2 (de) 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
WO1996006926A1 (fr) * 1994-08-30 1996-03-07 Ajinomoto Co., Inc. Procede pour produire de la l-valine et de la l-leucine
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
CA2170839A1 (en) * 1995-03-01 1996-09-02 Janet Macinnes Bacterial preparations, method for producing same, and their use as vaccines
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5840556A (en) * 1996-05-08 1998-11-24 The United States Of America As Represented By The Department Of Agriculture Molecular genetic construction of vaccine strains of pasteurellaceae
ZA974809B (en) * 1996-05-31 1998-01-23 Akzo Nobel Nv Live attenuated RTX-producing bacteria of the family pasteurellaceae.
US6020474A (en) * 1997-01-15 2000-02-01 Incyte Pharmaceuticals, Inc. ATP synthase subunits
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
HK1045856A1 (zh) * 1999-04-09 2002-12-13 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2000078922A2 (en) * 1999-06-21 2000-12-28 North Carolina State University Acid-inducible promoters for gene expression
AU4204800A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase

Also Published As

Publication number Publication date
EP2281833B1 (en) 2014-07-02
US20120148625A1 (en) 2012-06-14
JP5973634B2 (ja) 2016-08-23
EP2281834B1 (en) 2015-03-04
US8974798B2 (en) 2015-03-10
CN1351653A (zh) 2002-05-29
US20100322975A1 (en) 2010-12-23
JP2013121347A (ja) 2013-06-20
KR20010112937A (ko) 2001-12-22
NZ514883A (en) 2004-03-26
AU4077600A (en) 2000-11-14
EP1860117A2 (en) 2007-11-28
KR20070011622A (ko) 2007-01-24
KR20060134225A (ko) 2006-12-27
JP5377433B2 (ja) 2013-12-25
MXPA01010207A (es) 2003-07-21
EP2281834A2 (en) 2011-02-09
CA2366520A1 (en) 2000-10-19
ES2439645T3 (es) 2014-01-24
EP2281835B1 (en) 2013-11-06
US9289486B2 (en) 2016-03-22
US20090202594A1 (en) 2009-08-13
BR0009663A (pt) 2002-04-09
US20070237793A1 (en) 2007-10-11
US20150182615A1 (en) 2015-07-02
JP4892134B2 (ja) 2012-03-07
EP2281833A2 (en) 2011-02-09
EP1171577A2 (en) 2002-01-16
EP2281833A3 (en) 2011-11-30
HK1045856A1 (zh) 2002-12-13
WO2000061724A2 (en) 2000-10-19
AU780887B2 (en) 2005-04-21
KR20060116041A (ko) 2006-11-13
NZ530012A (en) 2005-10-28
JP2010284165A (ja) 2010-12-24
CA2366520C (en) 2013-10-01
US7763262B2 (en) 2010-07-27
EP2281834A3 (en) 2011-11-23
AU2005203189A1 (en) 2005-08-18
WO2000061724A3 (en) 2001-02-01
EP2281835A3 (en) 2011-11-23
JP2002541790A (ja) 2002-12-10
AU2005203189B2 (en) 2007-12-20
EP2281835A2 (en) 2011-02-09
AR029622A1 (es) 2003-07-10
JP2016019528A (ja) 2016-02-04
EP1860117A3 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
ES2535961T3 (es) Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
EP2455465A3 (en) Amylase Variants
MX9706823A (es) Una composicion mejorada de detergente para lavar ropa que contiene amilasa.
GR3026180T3 (en) Alkaline bacillus lipases, coding dna sequences therefor and bacilli which produce these lipases.
AR010340A1 (es) COMPOSICIoN PARA HORNEADO, USO DE DICHA COMPOSICIoN Y USO DEL POLIPÉPTIDO DE DICHA COMPOSICIoN.
NO970609L (no) Forbedret rensningssammensetning
ATE250629T1 (de) Für säugetierphosphodiesterasen kodierende dns
FI953797A0 (fi) Hapettumisenkestävä alfa-amylaasi
MX9605358A (es) Variantes de subtilicina 309 con absorcion disminuida e hidrolisis aumentada.
DE60310264D1 (en) Thermostabile alpha-amylase
MX9706841A (es) Variantes de proteinasa k que tienen adsorcion reducida e hidrolisis incrementada.
MX9706851A (es) Variantes de subtilisina carlseberg que tienen adsorcion reducida e hidrolisis incrementada.
DE60318391D1 (de) Bakteriophagen-lysin
BR9407393A (pt) Protease processo para preparação e uso da mesma cultura biologicamente pura de uma linhagem de bacillus sp composição detergente aditivo de detergéncia e processo de lavagem
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
MX9706847A (es) Variantes de subtilisina dy que tienen adsorcion reducida e hidrolisis incrementada.
AU3230797A (en) Dna encoding dp. 75 and a process for its use
WO2003086277A3 (en) Attenuated gram negative bacteria
MX9706846A (es) Variantes de termitasa que tienen adsorcion reducida e hidrolisis incrementada.
BR9506038A (pt) Dna clonato vetor recombinante e planta
ATE274061T1 (de) Nukleotid sequenzen kodierend für das lysr2 gen
IL135759A0 (en) Epoxide hydrolase
DE60230717D1 (de) Attenuirte Gram-negative Bakterien
HUP0001969A2 (hu) Az NNT-1 neurotróf faktor
WO1998032849A3 (en) Polynucleotide associated with the bo or bor syndrome, its corresponding polypeptide and diagnostic and therapeutic applications